This trial will evaluate neoadjuvant osimertinib with or without chemotherapy vs. chemotherapy alone in patients with resectable, EGFR-mutated, stage II-IIIB NSCLC, with major pathological response as the primary end point (33). Here, EGFR is linked to non-small cell lung carcinoma.